ImClone (IMCLE) reported its delayed fourth-quarter and full-year results for 2002 on Monday.
For the fourth quarter of last year, the company posted a loss of $39 million, or 54 cents a share, compared with a loss of $56 million, or 77 cents a share, the year-ago period. For the full year, ImClone said it lost $158 million, or $2.15 a share, compared with a loss of $128 million, or $1.84 a share, in 2001.
ImClone had delayed filing its results because it said its former chief executive, Sam Waksal, and other executives had failed to pay income taxes on some stock options and warrants.
Waksal was recently sentenced to seven years in prison for trying to unload ImClone shares ahead of news that the Food and Drug Administration wouldn't review the company's Erbitux cancer treatment.
Ironically, ImClone recently presented data showing Erbitux had a positive effect in the treatment of colon cancer patients, and the company's shares have risen almost 200% year to date.
"Today's filing shows ImClone is taking steps in the right direction and beginning to restore some order," said Cory W. Kasimov, equity analyst at Ryan Beck & Co, which doesn't have any banking relationship with ImClone. "But its future will hinge on the approval of Erbitux."
Imclone shares were down 60 cents, or almost 2%, at $30.25 late Monday.